Unusual Symptoms

Lab Test Genecept Assay Report Page 2 June 25, 2015


Drug Interaction Summary:

This summary provides a listing of implications for psychotropic medications specific to your patient's genetic profile
 
Use as Directed
Therapeutic Options
Use With Caution
Medication
Primary metabolizing enzyme(s)
No known Gene-Drug Interactions
Options which may be used if clinically indicated
Serum levels may be ↑ [reduced dose may be required]
Serum levels may be ↓ [increased dose may be required]
Increased risk for adverse events or poor response
Antidepressants
Amitriptyline (Elavil®) 2D6, 2C19
X
  
Amoxapine 2D6
X
  
Bupropion (Wellbutrin®) -
X
  
Citalopram (Celexa®) 2C19, 3A4
 
  
X
Clomipramine (Anafranil®) 2D6, 2C19
X
  
Desipramine (Norpramin®) 2D6
X
  
Desvenlafaxine (Pristiq®) -
X
  
Doxapin (Sinequan®) 2D6
X
  
Duloxetine (Cymbalta®) 2D6
X
  
Escitalopram (Lexapro®) 2D6, 2C19
 
  
X
Fluoxetine (Prozac®) 2D6
 
  
X
Fluvoxamine (Luvox®) 2D6
 
  
X
Imipramine (Tofranil®) 2D6, 3A4
X
  
Levomilnacipran (Fetzima®) 3A4
X
  
Mirtazapine (Remeron®) 2D6, 3A4
X
  
Nefazodone (Serzone®) 2D6, 3A4
X
  
Nortriptyline (Pamelor®) 2D6
X
  
Paroxetine (Paxil®) 2D6
 
  
X
Phenelzine (Nardil®) -
X
  
Protriptyline (Vivactil®) 2D6
X
  
Selegiline (Eldepry®) -
X
  
Sertraline (Zoloft®) -
 
  
X
Tranylcypromine (Parnate®) -
X
  
Trazodone (Desyrel®) 3A4
X
  
Trimipramine (Surmontil®) 2D6, 2C19
X
  
Venlafaxine (Effexor®)[1] 2D6, 2C19
X
  
Vilazodone (Vibryd®) 3A4
X
  
Vortioxetine (Brintellix®)[4] 2D6
X
  
Miscellaneous Stimulants; NRIs; a2-Agonists
Armodafinil (Nuvigil®) 3A4
X
  
Atomoxetine (Strattera®)[4] 2D6
X
  
Clonidine (Kapvay®) -
X
  
Guanfacine (Intuniv®) 3A4
X
  
Modafinil (Provigil®) 3A4
X
  

[1} Prodrug - requiring activation by the liver; 2D6 IMs/PMs may experience lower efficacy and increased side effects due to reduced conversion to the active metabolite and higher levels of the inactive parent drug; 2D6 UMs may experience increased conversion of the parent drug, and higher levels of the active metabolite
[2] Indeterminate - gene drug interaction exists, but clinical impact is indeterminate or genotype could not be determined
[3] These medications are listed both as therapeutic options (due to a CACNA1C variation) and as medications to use with caution (due to the presence of a DRD2 or 5HT2C variation and the potential interaction with atypical antipsychotics). The patient's clinical presentation should be fully considered to determine risks vs. benefits of using these particular treatments.
[4] - Medication has manufacturer dose-administration FDA labeling; see the Genecept Assay Report Interpretation Guide


<- Previous Next ->


email: 

Page Revised: September 5, 2015